Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. - Wikidata - awgldk - TriplyDB

Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma.

Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma.

http://www.wikidata.org/entity/Q31015437

about

Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods Clinical applications for diffusion magnetic resonance imaging in radiotherapy Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2 A Pilot Study of Quantitative MRI Parametric Response Mapping of Bone Marrow Fat for Treatment Assessment in Myelofibrosis.DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma A novel method for volumetric MRI response assessment of enhancing brain tumors Low Dose Focused Ultrasound Induces Enhanced Tumor Accumulation of Natural Killer Cells.Application of diffusion-weighted magnetic resonance imaging to predict the intracranial metastatic tumor response to gamma knife radiosurgery.Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS): features and potential applications in oncology.Optimal experimental design for filter exchange imaging: Apparent exchange rate measurements in the healthy brain and in intracranial tumors Diffusion-weighted MRI as a biomarker for treatment response in glioma Invited review--neuroimaging response assessment criteria for brain tumors in veterinary patients Apparent diffusion coefficient is a prognostic factor of head and neck squamous cell carcinoma treated with radiotherapy.Imaging biomarkers for antiangiogenic therapy in malignant gliomas.Diffusion-weighted MRI in neuro-oncology.Advanced magnetic resonance imaging of the physical processes in human glioblastoma.Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: a multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma.Differentiation of Low- and High-Grade Pediatric Brain Tumors with High b-Value Diffusion-weighted MR Imaging and a Fractional Order Calculus Model Diffusion MRI in early cancer therapeutic response assessment.Independent prognostic value of pre-treatment 18-FDG-PET in high-grade gliomas.The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome.Integrative analysis of diffusion-weighted MRI and genomic data to inform treatment of glioblastoma.Advanced MRI in the management of adult gliomas.A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone Diffusion magnetic resonance imaging: an imaging treatment response biomarker to chemoradiotherapy in a mouse model of squamous cell cancer of the head and neck A feasibility study of parametric response map analysis of diffusion-weighted magnetic resonance imaging scans of head and neck cancer patients for providing early detection of therapeutic efficacy.Quantitative imaging to assess tumor response to therapy: common themes of measurement, truth data, and error sources Apparent diffusion coefficient of glial neoplasms: correlation with fluorodeoxyglucose-positron-emission tomography and gadolinium-enhanced MR imaging.Voxel-by-voxel functional diffusion mapping for early evaluation of breast cancer treatment Diffusion-weighted MRI for assessment of early cancer treatment response.Role and value of diffusion-weighted MRI in the radiotherapeutic management of head and neck cancer.Advances in MRI assessment of gliomas and response to anti-VEGF therapy.ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain Assessment of therapeutic response and treatment planning for brain tumors using metabolic and physiological MRI.Validation of an algorithm for the nonrigid registration of longitudinal breast MR images using realistic phantoms.In-vivo visualization of tumor microvessel density and response to anti-angiogenic treatment by high resolution MRI in mice Assessment of multiparametric MRI in a human glioma model to monitor cytotoxic and anti-angiogenic drug effects Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity.Predicting and monitoring cancer treatment response with diffusion-weighted MRI.

P2860

Q26774355-A9A108BB-7840-4DBF-BC35-C61B0210EEE8 Q26853516-08A8186A-2E51-4C75-A840-DEF9554EDABA Q27005757-5B2E42E8-FE69-4669-8EAB-68799E23ED25 Q27010096-0E38EBBD-28E7-4673-9F08-E60D0CC3C608 Q27342179-269E9373-1F9F-47BE-8398-6A043C359C65 Q28730443-DB3853DE-4C38-478A-AB54-A060D8DF65F9 Q28743259-5F34D424-360B-4D29-A741-2C8851D341E9 Q30398870-E3E6759D-D77E-42FB-B458-112EA22C9816 Q30457918-3E91E606-15C2-4379-B884-3B056AB34EFC Q30483058-8C3F2B50-5039-4823-8348-FB8C3F76573E Q30489078-50A8FCC5-A489-4196-99C8-8DBEB126C7D2 Q30660991-A995327A-5CD1-4106-BB42-D20F3D6BA427 Q30692995-E76CB62D-8F46-498F-A700-650E631C5DBE Q30730091-63A73796-A516-4F8F-BC2A-B65DDD7D1922 Q30764736-D5BB7894-CCBB-4A19-9F66-C00968DF87CE Q30838362-74C8C492-D1AA-418F-8EBC-C760A8281F0E Q30847284-79053CF2-AB70-4BC2-A9A0-C67FBCD75B4E Q30891381-C730E656-AA4A-43E7-AFAA-464F2A840EC7 Q30963767-5F166072-9AC8-49E6-92AE-1F1256EAFE52 Q31037179-36BEF6CA-2DCB-46B3-9F71-7BF7D8709F91 Q31043472-89FE2D35-0D35-436F-BCE6-4E5B42D88432 Q31043513-A263EA9A-F96A-4736-B994-ACF88A01E383 Q31113520-8FB11E7A-6869-45D1-9E3B-13E6DE59C972 Q31139548-950BB411-6E8C-4493-971E-2BD316374967 Q31140219-AE1B6CB8-7BF4-4690-8C09-899A8AC33424 Q33388183-98296F17-D0E4-4814-987F-329E4B073488 Q33496147-8CFB9961-3EF5-4C72-8679-0695A6DD6CF9 Q33517098-53D8DAB0-D1C2-46FF-8C0D-94FD62124781 Q33530806-75C9FE52-6579-4056-BE58-4F721F8AC119 Q33584285-1D2D01B0-0861-4BCC-B5F7-00BC5D2E4333 Q33588005-DD474FE5-2070-480A-9D68-D6296CB97C51 Q33690816-B761860B-13AB-4E01-AEC2-6D7308EDB840 Q33793253-F372B9B0-E95E-4910-B41A-E36090EC1E97 Q33870872-6592947C-BB2F-4834-BF35-D491791A5EBF Q33888366-13320EF7-4D63-4673-9486-97E2665D37A0 Q33898515-D87396D0-4C6D-46AD-AE0C-D9884F723196 Q33900712-165A03AE-D886-48EC-9576-C984FED82675 Q33933312-AA5747C8-6991-409E-A7E6-BD36C4C681EC Q33989536-787F98EB-91AE-4264-AFBA-773E2352A914 Q34052992-3A9A539E-9BF4-44D6-BB50-A0FD8F4803D0

P2860

Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma.

http://www.wikidata.org/entity/Q31015437

description

2005 nî lūn-bûn

@nan

2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Evaluation of the functional d ...... survival in high-grade glioma.

@ast

Evaluation of the functional d ...... survival in high-grade glioma.

@en

type

label

Evaluation of the functional d ...... survival in high-grade glioma.

@ast

Evaluation of the functional d ...... survival in high-grade glioma.

@en

prefLabel

Evaluation of the functional d ...... survival in high-grade glioma.

@ast

Evaluation of the functional d ...... survival in high-grade glioma.

@en

P1433

Q31015437-873A9A84-8B4A-4319-839C-95CA003B4644

P1476

Q31015437-9D1B6618-A657-4DA3-BFE3-02A9FF1C10FB

P2093

Q31015437-0CEA0352-3279-4F77-9738-B2F46BC72B86

Q31015437-1767AD5A-06DE-4532-AE4F-73B91CF7395F

Q31015437-1F8F22DD-D78B-4F93-8491-8B454B208768

Q31015437-2841077B-5C79-4917-A021-B7B7EB27CE1D

Q31015437-37DA015B-31A1-41CA-BA44-4A8ED59EABC7

Q31015437-3BF1E511-F3CA-4D73-BF16-9F25A6D09FB7

Q31015437-3F5E6E28-89D4-4FB4-80D7-0B4672F3D021

Q31015437-68BF2578-378F-43BE-8E15-C410AF4FA57E

Q31015437-93B0529B-4C0A-4EE7-819B-37132EBF18DF

Q31015437-951CBD94-B49B-452C-850D-D975BF736118

P2860

Q31015437-0419846A-8765-4D29-B620-DF1B23005558

Q31015437-0F0B2FB7-6957-4B6C-BF93-2699CA7998D2

Q31015437-21370757-8883-4B85-B06D-3A460FA968FF

Q31015437-2D0B7DF6-8FC7-4BA8-B649-FDF1708CEB81

Q31015437-2F0AFFE6-2680-47A6-8B4B-FD5D5A11F008

Q31015437-3A519CB7-7FFA-45FA-B463-29F39367456F

Q31015437-448480D2-8A40-49DE-BC99-FBC9F9D11FB6

Q31015437-4FFADC96-AE1E-4C2D-ABCE-470A2185622F

Q31015437-5241D88D-D25B-4543-9198-4F98EC60C1BA

Q31015437-5A6D68F7-B5B2-43B6-AD52-CC053F07AB29

P304

Q31015437-6E9C3002-0740-4024-907F-9E55BB2BA64A

P31

Q31015437-75571911-5C8B-42C8-80C2-A035390866ED

P356

Q31015437-54A3544E-7479-4213-9FCD-E2B689E722FB

P407

Q31015437-C20E9946-1DE2-4FAB-AC6B-33103D64EDB1

P433

Q31015437-27659621-648D-47AE-B5CE-0ACEC1B91BF1

P478

Q31015437-15A0BD79-2AF1-4AF8-9E89-A900FD2608D3

P50

Q31015437-DA6F3BC2-85CF-41CD-B8BB-1F1AEB045B9A

P577

Q31015437-BFBE0CAC-DC59-45CE-A755-6692A99E43FF

P5875

Q31015437-1A9FA0C0-1C36-49E1-8FEE-820AF64A0F0F

P698

Q31015437-615F9D25-9CB5-4F97-BAA7-2AF586B3461D

P921

Q31015437-112323CE-5C37-4E4E-8DAF-E05571E8688B

P932

Q31015437-609F7719-CE05-43CC-9C58-4153FDAB598E

P356

PNAS.0508347102

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Evaluation of the functional d ...... survival in high-grade glioma.

@en

P2093

Alnawaz Rehemtulla

http://www.w3.org/2001/XMLSchema#string

Bradford A Moffat

http://www.w3.org/2001/XMLSchema#string

Brian D Ross

http://www.w3.org/2001/XMLSchema#string

Charles R Meyer

http://www.w3.org/2001/XMLSchema#string

Christina I Tsien

http://www.w3.org/2001/XMLSchema#string

Daniel A Hamstra

http://www.w3.org/2001/XMLSchema#string

Douglas J Quint

http://www.w3.org/2001/XMLSchema#string

Larry Junck

http://www.w3.org/2001/XMLSchema#string

Stephen S Gebarski

http://www.w3.org/2001/XMLSchema#string

Suresh K Mukherji

http://www.w3.org/2001/XMLSchema#string

P2860

Diffusion tensor MR imaging of the human brain

Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors.

Primary brain tumours in adults.

Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging.

The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies.

Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy.

Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response.

P304

16759-16764

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0508347102

http://www.w3.org/2001/XMLSchema#string

P407

P433

46

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P50

Thomas L Chenevert

P577

2005-11-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7501221

http://www.w3.org/2001/XMLSchema#string

P698

16267128

http://www.w3.org/2001/XMLSchema#string

P921

P932

1276616

http://www.w3.org/2001/XMLSchema#string